Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer

European Respiratory Journal

Volumn 10, Issue 11, 1997, Pages 2529-2534

  Bury, Th ^a,b   Dowlati, A ^a   Paulus, P ^a   Corhay, J L ^a   Hustinx, R ^a   Ghaye, B ^a   Radermecker, M ^a   Rigo, P ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CHU SART TILMAN   (Belgium)

Author keywords

Non small cell lung cancer; Positron emission tomography scan; Presurgical staging

Indexed keywords

DEOXYGLUCOSE; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; FLUORINE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EMISSION TOMOGRAPHY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SCINTISCANNING; MAJOR CLINICAL STUDY; POSITRON; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STAGING; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; LUNG TUMOR; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PREDICTION AND FORECASTING; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0031282954     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.97.10112529     Document Type: Article

References (26)

1. 2 disease) in non-small cell carcinoma of the lung. Thorac Cardiovasc Surg 1990; 99: 48-53.
2. Kadvi MA, Dussek JE. Survival and prognosis following resection of primary non-small cell bronchogenic carcinoma. Eur J Cardiothoracic Surg 1991; 5: 132-136.
3. Quint L, Glazer G, Orringer M, Francis I, Bookstein F. Mediastinal lymph node detection and sizing at CT and autopsy. Am J Roentgenol 1986; 147: 469-472.
4. Reinig J, Doppman J, Dwyer A. Adrenal masses differentiated by MR. Radiology 1986; 158: 81-84.
5. McLoud T, Bourgouin P, Greenberg R, et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 1992; 182: 319-323.
6. Bragg DG. Current applications of imaging procedures in the patient with lung cancer. Int J Radiat Oncol Biol Phys 1991; 21: 847-885.
7. Whittlesey D. Prospective computed tomographic screening in the staging of bronchogenic cancer. J Thorac Cardiovasc Surg 1988; 95: 876-882.
8. Webb W, Gastonis C, Zerhouni E, et al. CT and MR imaging in staging of non-small cell bronchogenic carcinoma: a report of the Radiologic Diagnostic Oncology Group. Radiology 1991; 178: 705-712.
9. Quint L, Francis I, Wahl R, Gross B. Imaging of lung cancer. In: Pass I, Mitchell J, Johnson D, Turrisi A. Wolfberg E ed. Lung Cancer: Principles and Practice. Philadelphia, Lippincott-Raven Publishers, 1996; 437-470.
10. Hatamaka M. Transport of sugars in tumor cell membranes. Biochem Biophys Acta 1974; 355: 74-104.
11. Flier J, Mueckleer M, Usher P, Lodish H. Elevated levels of glucose transport and transporter messenger RNA are induced by ras and sarc oncogens. Science 1987; 235: 1492-1495.
12. Bury T, Dowlati A, Paulus P, et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J 1996; 9: 410-414.
13. Bury T, Paulus P, Dowlati A, et al. Staging of the mediastinum: value of PET imaging in nonsmall cell lung cancer. Eur Respir J 1996; 9: 2560-2564.
14. Bury T, Dowlati A, Paulus P, et al. Staging of nonsmall cell lung cancer by whole-body FDG positron emission tomography. Eur J Nucl Med 1996; 23: 204-206.
15. Glantz SA. Confidence intervals. In: Jefferies J, Englis M, eds. Primer of Statistics, 3rd ed. New York, McGraw-Hill, 1992; pp. 188-192.
16. Wahl R, Quint L, Greenough R, Meyer C, White R, Orringer M. Staging of mediastinal non-small cell lung cancer with FDG-PET, CT and fusion images: preliminary prospective evaluation. Radiology 1994; 191: 371-377.
17. Chin R, Ward R, Keyes J, et al. Mediastinal staging of NSCLC with positron emission tomography. Am J Respir Crit Care Med 1995; 152: 2090-2096.
18. Valk P, Pounds T, Hopkins D, Haseman M, et al. Staging of NSCLC by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995; 60: 1573-1582.
19. Sazon D, Santiago S, Hoo G, et al. Fluorodeoxyglucose-Positron Emission Tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med 1996; 153: 417-421.
20. Scott W, Gobar L, Terry J, Dewan N, Sunderland J. Mediastinal lymph node staging of non-small cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg 1996; 111: 642-648.
21. Steinert H, Hauser M, Allermann F, et al. Non-small cell lung cancer: nodal staging with FDG-PET versus CT with correlative lymph node mapping and sampling. Radiology 1997; 202: 441-446.
22. Lewis P, Griffin S, Marsden P, et al. Whole-body 18FDG positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994; 344: 1265-1266.
23. Mittman C, Bruderman I. Lung cancer: to operate or not? Am Rev Respir Dis 1977; 116: 1477-1496.
24. Larcos G, Maisey M. FDG-PET screening for cerebral metastasis in patients with suspected malignancy. Nucl Med Com 1996; 17: 197-198.
25. Gambhir S, Hoh C, Phelps M, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of nonsmall cell lung carcinoma. J Nucl Med 1996; 37: 1428-1436.
26. Armstrong P, Reznek R, Phillips R. Diagnostic imaging of lung cancer. In: Carcinoma of the lung. Eur Respir Mon 1995; 1: 137-187.